Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial
This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild ren...
Gespeichert in:
| Veröffentlicht in: | Naunyn-Schmiedeberg's archives of pharmacology 2021-06, Vol.394 (6), p.1275-1283 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1283 |
|---|---|
| container_issue | 6 |
| container_start_page | 1275 |
| container_title | Naunyn-Schmiedeberg's archives of pharmacology |
| container_volume | 394 |
| creator | Ning, Xiaoyi Kuang, Yun Yang, Guoping Xie, Jinlian Miao, Da Guo, Chengxian Huang, Zhijun |
| description | This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in
Clinicaltrials.gov
(NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin. |
| doi_str_mv | 10.1007/s00210-020-02037-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8208902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475532843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-71220165852fee0657f2831840bdfedb9b4f1c664aed9d7cb7660e88beeed43d3</originalsourceid><addsrcrecordid>eNp9Uctu1DAUtRCIDoUfYIEssWET6mfisEBCoxYqVWIDa8txrqeuHHuwk6LhL_hjPJ3SBwsWlq_uefj6HoReU_KeEtKdFEIYJQ1hN4d3DX-CVlRw1tCesqdoVXHVUNarI_SilCtCSEulfI6OOBdEtKpfod_n0YUFogWcHM4QTcA-lsU5b31t73CK2MTZ22Q2S6gVBufAzqV2R1yMg3m3l_402ZnsY1Xj9aWPUABvzVw95vKhck3YFV-wy2nCBucqTpP_BSO2Kc45hVDLOXsTXqJnzoQCr27vY_T97PTb-ktz8fXz-frTRWOlIHPTUcYIbaWSzAGQVnaOKU6VIMPoYBz6QThq21YYGPuxs0PXtgSUGgBgFHzkx-jjwXe7DBOMtg6aTdDb7CeTdzoZrx8j0V_qTbrWihHVE1YN3t0a5PRjgTLryRcLoS4J0lI0E52UnCnBK_XtP9SrtOS6k8qSgso6Pd8bsgPL5lRKBnc3DCV6n7g-JK5r2vomcb23fvPwG3eSvxFXAj8QSoXiBvL92_-x_QOqH7ps</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541565732</pqid></control><display><type>article</type><title>Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ning, Xiaoyi ; Kuang, Yun ; Yang, Guoping ; Xie, Jinlian ; Miao, Da ; Guo, Chengxian ; Huang, Zhijun</creator><creatorcontrib>Ning, Xiaoyi ; Kuang, Yun ; Yang, Guoping ; Xie, Jinlian ; Miao, Da ; Guo, Chengxian ; Huang, Zhijun</creatorcontrib><description>This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in
Clinicaltrials.gov
(NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin.</description><identifier>ISSN: 0028-1298</identifier><identifier>EISSN: 1432-1912</identifier><identifier>DOI: 10.1007/s00210-020-02037-3</identifier><identifier>PMID: 33404689</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adverse events ; Aged ; Anticoagulants ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - pharmacology ; Asians ; Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Creatinine ; Creatinine - metabolism ; Dosage ; Dose-Response Relationship, Drug ; Female ; Hemorrhage - chemically induced ; Humans ; International Normalized Ratio ; Male ; Middle Aged ; Multiple regression analysis ; Neurosciences ; Original ; Original Article ; Pharmacology/Toxicology ; Prospective Studies ; Renal function ; Renal insufficiency ; Renal Insufficiency - complications ; Renal Insufficiency - physiopathology ; Safety ; Single-Blind Method ; Statistical analysis ; Thromboembolism ; Time Factors ; Warfarin ; Warfarin - administration & dosage ; Warfarin - adverse effects ; Warfarin - pharmacology</subject><ispartof>Naunyn-Schmiedeberg's archives of pharmacology, 2021-06, Vol.394 (6), p.1275-1283</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-71220165852fee0657f2831840bdfedb9b4f1c664aed9d7cb7660e88beeed43d3</citedby><cites>FETCH-LOGICAL-c540t-71220165852fee0657f2831840bdfedb9b4f1c664aed9d7cb7660e88beeed43d3</cites><orcidid>0000-0002-6332-6716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00210-020-02037-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00210-020-02037-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33404689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ning, Xiaoyi</creatorcontrib><creatorcontrib>Kuang, Yun</creatorcontrib><creatorcontrib>Yang, Guoping</creatorcontrib><creatorcontrib>Xie, Jinlian</creatorcontrib><creatorcontrib>Miao, Da</creatorcontrib><creatorcontrib>Guo, Chengxian</creatorcontrib><creatorcontrib>Huang, Zhijun</creatorcontrib><title>Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial</title><title>Naunyn-Schmiedeberg's archives of pharmacology</title><addtitle>Naunyn-Schmiedeberg's Arch Pharmacol</addtitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><description>This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in
Clinicaltrials.gov
(NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin.</description><subject>Adverse events</subject><subject>Aged</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - pharmacology</subject><subject>Asians</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Creatinine - metabolism</subject><subject>Dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple regression analysis</subject><subject>Neurosciences</subject><subject>Original</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><subject>Prospective Studies</subject><subject>Renal function</subject><subject>Renal insufficiency</subject><subject>Renal Insufficiency - complications</subject><subject>Renal Insufficiency - physiopathology</subject><subject>Safety</subject><subject>Single-Blind Method</subject><subject>Statistical analysis</subject><subject>Thromboembolism</subject><subject>Time Factors</subject><subject>Warfarin</subject><subject>Warfarin - administration & dosage</subject><subject>Warfarin - adverse effects</subject><subject>Warfarin - pharmacology</subject><issn>0028-1298</issn><issn>1432-1912</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9Uctu1DAUtRCIDoUfYIEssWET6mfisEBCoxYqVWIDa8txrqeuHHuwk6LhL_hjPJ3SBwsWlq_uefj6HoReU_KeEtKdFEIYJQ1hN4d3DX-CVlRw1tCesqdoVXHVUNarI_SilCtCSEulfI6OOBdEtKpfod_n0YUFogWcHM4QTcA-lsU5b31t73CK2MTZ22Q2S6gVBufAzqV2R1yMg3m3l_402ZnsY1Xj9aWPUABvzVw95vKhck3YFV-wy2nCBucqTpP_BSO2Kc45hVDLOXsTXqJnzoQCr27vY_T97PTb-ktz8fXz-frTRWOlIHPTUcYIbaWSzAGQVnaOKU6VIMPoYBz6QThq21YYGPuxs0PXtgSUGgBgFHzkx-jjwXe7DBOMtg6aTdDb7CeTdzoZrx8j0V_qTbrWihHVE1YN3t0a5PRjgTLryRcLoS4J0lI0E52UnCnBK_XtP9SrtOS6k8qSgso6Pd8bsgPL5lRKBnc3DCV6n7g-JK5r2vomcb23fvPwG3eSvxFXAj8QSoXiBvL92_-x_QOqH7ps</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Ning, Xiaoyi</creator><creator>Kuang, Yun</creator><creator>Yang, Guoping</creator><creator>Xie, Jinlian</creator><creator>Miao, Da</creator><creator>Guo, Chengxian</creator><creator>Huang, Zhijun</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6332-6716</orcidid></search><sort><creationdate>20210601</creationdate><title>Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial</title><author>Ning, Xiaoyi ; Kuang, Yun ; Yang, Guoping ; Xie, Jinlian ; Miao, Da ; Guo, Chengxian ; Huang, Zhijun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-71220165852fee0657f2831840bdfedb9b4f1c664aed9d7cb7660e88beeed43d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Aged</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - pharmacology</topic><topic>Asians</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Creatinine - metabolism</topic><topic>Dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple regression analysis</topic><topic>Neurosciences</topic><topic>Original</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><topic>Prospective Studies</topic><topic>Renal function</topic><topic>Renal insufficiency</topic><topic>Renal Insufficiency - complications</topic><topic>Renal Insufficiency - physiopathology</topic><topic>Safety</topic><topic>Single-Blind Method</topic><topic>Statistical analysis</topic><topic>Thromboembolism</topic><topic>Time Factors</topic><topic>Warfarin</topic><topic>Warfarin - administration & dosage</topic><topic>Warfarin - adverse effects</topic><topic>Warfarin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ning, Xiaoyi</creatorcontrib><creatorcontrib>Kuang, Yun</creatorcontrib><creatorcontrib>Yang, Guoping</creatorcontrib><creatorcontrib>Xie, Jinlian</creatorcontrib><creatorcontrib>Miao, Da</creatorcontrib><creatorcontrib>Guo, Chengxian</creatorcontrib><creatorcontrib>Huang, Zhijun</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ning, Xiaoyi</au><au>Kuang, Yun</au><au>Yang, Guoping</au><au>Xie, Jinlian</au><au>Miao, Da</au><au>Guo, Chengxian</au><au>Huang, Zhijun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial</atitle><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle><stitle>Naunyn-Schmiedeberg's Arch Pharmacol</stitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>394</volume><issue>6</issue><spage>1275</spage><epage>1283</epage><pages>1275-1283</pages><issn>0028-1298</issn><eissn>1432-1912</eissn><abstract>This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in
Clinicaltrials.gov
(NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33404689</pmid><doi>10.1007/s00210-020-02037-3</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6332-6716</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-1298 |
| ispartof | Naunyn-Schmiedeberg's archives of pharmacology, 2021-06, Vol.394 (6), p.1275-1283 |
| issn | 0028-1298 1432-1912 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8208902 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adverse events Aged Anticoagulants Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - pharmacology Asians Biomedical and Life Sciences Biomedicine Clinical trials Creatinine Creatinine - metabolism Dosage Dose-Response Relationship, Drug Female Hemorrhage - chemically induced Humans International Normalized Ratio Male Middle Aged Multiple regression analysis Neurosciences Original Original Article Pharmacology/Toxicology Prospective Studies Renal function Renal insufficiency Renal Insufficiency - complications Renal Insufficiency - physiopathology Safety Single-Blind Method Statistical analysis Thromboembolism Time Factors Warfarin Warfarin - administration & dosage Warfarin - adverse effects Warfarin - pharmacology |
| title | Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T12%3A31%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20renal%20insufficiency%20on%20anticoagulant%20effects%20and%20safety%20of%20warfarin%20in%20Chinese%20patients:%20analysis%20from%20a%20randomized%20controlled%20trial&rft.jtitle=Naunyn-Schmiedeberg's%20archives%20of%20pharmacology&rft.au=Ning,%20Xiaoyi&rft.date=2021-06-01&rft.volume=394&rft.issue=6&rft.spage=1275&rft.epage=1283&rft.pages=1275-1283&rft.issn=0028-1298&rft.eissn=1432-1912&rft_id=info:doi/10.1007/s00210-020-02037-3&rft_dat=%3Cproquest_pubme%3E2475532843%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541565732&rft_id=info:pmid/33404689&rfr_iscdi=true |